Markets:

Overview

News

Currencies

International

Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

15.21 -0.16 (-1.07%)

Streaming Delayed Price Updated: 10:06 AM EST, Feb 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MoonLake Immunotherapeutics - Class A Ordinary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

November 05, 2023

From MoonLake Immunotherapeutics AG

Via GlobeNewswire

MoonLake Immunotherapeutics' Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst ↗

October 16, 2023

MoonLake Immunotherapeutics (NASDAQ: MLTX) announced 24-week topline results from its Phase 2 MIRA trial of sonelokimab for moderate-to-severe hidradenitis suppurativa (HS), following the 12-week...

Via Benzinga

Lululemon, PCTEL, Consolidated Communications, Other Stocks Jumping Higher On Monday ↗

October 16, 2023

U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Monday. Here are some stocks recording big gains in today’s session.

Via Benzinga

Topics Stocks

Where MoonLake Stands With Analysts ↗

October 16, 2023

Via Benzinga

The Latest Analyst Ratings for MoonLake ↗

September 18, 2023

Via Benzinga

Expert Ratings for MoonLake ↗

August 31, 2023

Via Benzinga

10 Analysts Have This to Say About MoonLake ↗

August 14, 2023

Via Benzinga

Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

October 16, 2023

Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday.

Via Benzinga

Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout ↗

October 16, 2023

MoonLake says it's skin-disease treatment showed improved promise in a 24-week testing update.

Via Investor's Business Daily

Analyst Expectations for MoonLake's Future ↗

July 26, 2023

Via Benzinga

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

October 15, 2023

From MoonLake Immunotherapeutics AG

Via GlobeNewswire

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress

October 11, 2023

From MoonLake Immunotherapeutics AG

Via GlobeNewswire

7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio ↗

September 27, 2023

Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.

Via InvestorPlace

These 8 Stocks Are Outperforming Nvidia In 2023 ↗

September 18, 2023

Carvana has surged 1,001%, leading huge winners this year.

Via Investor's Business Daily

Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

September 12, 2023

Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock.

Via Benzinga

Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday ↗

September 12, 2023

A competitor's clinical trial stumble may be benefiting MoonLake.

Via The Motley Fool

Casey's General Stores, Cognyte Software, Beauty Health And Other Big Stocks Moving Higher On Tuesday ↗

September 12, 2023

U.S. stocks traded lower, with the Dow Jones gaining around 90 points on Tuesday. Here are some big stocks recording gains in today’s session. Shengfeng Development Limited (NASDAQ: SFWL) shares jumped...

Via Benzinga

Topics Stocks

The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 19% ↗

September 12, 2023

The companies are both working on treatments for a rare skin disease.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 12, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 11, 2023

Via Benzinga

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

September 06, 2023

From MoonLake Immunotherapeutics AG

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 31, 2023

Via Benzinga

Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts ↗

August 31, 2023

Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023 ↗

August 31, 2023

Via Benzinga

The 7 Most Promising Momentum Stocks to Own Now ↗

August 31, 2023

These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility.

Via InvestorPlace

MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

August 10, 2023

From MoonLake Immunotherapeutics AG

Via GlobeNewswire

MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts

July 25, 2023

From MoonLake Immunotherapeutics AG

Via GlobeNewswire

10 Short Squeeze Stocks To Watch: Baosheng Media, Toro Corp, Getty Images And More ↗

July 18, 2023

Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among...

Via Benzinga

Price Target For MoonLake Doubled: Analyst Says Lead Program Has 'Best-In-Class Profile' ↗

July 17, 2023

HC Wainwright has increased the price target for MoonLake Immunotherapeutics (NASDAQ: MLTX) from $37 to $75

Via Benzinga

Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories ↗

July 17, 2023

Benzinga

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.